Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

703.30 +2.85 (+0.41%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

October 29, 2025

From argenx SE

Via GlobeNewswire

ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗

October 24, 2025

Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.

Via Chartmill

argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

October 23, 2025

From argenx SE

Via GlobeNewswire

If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today ↗

October 22, 2025

Via Benzinga

How Do Investors Really Feel About argenx SE? ↗

October 13, 2025

Via Benzinga

12 Analysts Have This To Say About argenx ↗

September 18, 2025

Via Benzinga

Is argenx Gaining or Losing Market Support? ↗

September 08, 2025

Via Benzinga

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗

October 22, 2025

Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Via The Motley Fool

Topics Workforce

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

October 15, 2025

From argenx SE

Via GlobeNewswire

Assessing argenx: Insights From 12 Financial Analysts ↗

October 13, 2025

Via Benzinga

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗

October 13, 2025

Via Benzinga

Assessing argenx: Insights From 11 Financial Analysts ↗

August 25, 2025

Via Benzinga

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

October 03, 2025

From argenx SE

Via GlobeNewswire

ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy ↗

October 03, 2025

ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum.

Via Chartmill

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

September 29, 2025

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of...

Via Benzinga

Price Over Earnings Overview: argenx ↗

September 26, 2025

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up...

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

September 10, 2025

Via Benzinga

argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy ↗

September 10, 2025

Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability.

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

3 Healthcare Pathbreakers With Long-Term Tailwinds ↗

September 01, 2025

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

Via MarketBeat

argenx to Present at Upcoming Investor Conferences

August 28, 2025

From argenx SE

Via GlobeNewswire

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

August 27, 2025

Via Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win ↗

August 26, 2025

Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.

Via Benzinga

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗

August 26, 2025

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.

Via Benzinga

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

Argenx Tops Buy Point On Bullish Study, 850 Price Target ↗

August 25, 2025

Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage.

Via Investor's Business Daily

Argenx Targets FDA Label Expansion After Vyvgart Trial Success ↗

August 25, 2025

Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.